Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Large Decrease in Short Interest

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) saw a large decrease in short interest during the month of July. As of July 31st, there was short interest totaling 37,127 shares, a decrease of 53.9% from the July 15th total of 80,592 shares. Based on an average daily volume of 138,153 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.7% of the company’s stock are short sold.

Institutional Investors Weigh In On Regentis Biomaterials

A hedge fund recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new position in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned about 5.79% of Regentis Biomaterials as of its most recent SEC filing.

Regentis Biomaterials Stock Up 5.3%

NYSEAMERICAN:RGNT traded up $0.10 on Friday, reaching $2.00. 55,057 shares of the stock traded hands, compared to its average volume of 107,072. Regentis Biomaterials has a 12 month low of $1.23 and a 12 month high of $15.50. The company’s fifty day simple moving average is $2.97 and its 200 day simple moving average is $3.19.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.